• Je něco špatně v tomto záznamu ?

Progress on the development of Class A GPCR-biased ligands

P. Morales, MM. Scharf, M. Bermudez, A. Egyed, R. Franco, OK. Hansen, N. Jagerovic, J. Jakubík, GM. Keserű, DJ. Kiss, P. Kozielewicz, O. Larsen, M. Majellaro, A. Mallo-Abreu, G. Navarro, R. Prieto-Díaz, MM. Rosenkilde, E. Sotelo, H. Stark, T....

. 2025 ; 182 (14) : 3249-3300. [pub] 20240911

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc25015235

Grantová podpora
RRF-2.3.1-21-2022-00015 National Office of Research, Development and Innovation
FJC2021-047571-I Ministerio de Ciencia e Innovación
PID2020-118511RB-I00 Ministerio de Ciencia e Innovación
PID2021-124010OB-100 Ministerio de Ciencia e Innovación
PID2021-126600OB-I00 Ministerio de Ciencia e Innovación
PID2021-127833OB-I00 Ministerio de Ciencia e Innovación
PID2022-139197OA-I00 Ministerio de Ciencia e Innovación
20 0264 Cancerfonden
R01 DA0455698 NIH HHS - United States
470002134 German Research Foundation
GRK 2158 German Research Foundation
PG-22-0379-H-01 Swedish Society for Medical Research
NAP 3.0 Hungarian Academy of Sciences
ED431B 2020/43 Consellería de Cultura, Educación e Ordenación Universitaria of the Galician Government
ED431G 2019/03 Centro Singular de Investigación de Galicia Accreditation 2019-2022
FJC2021-047571-I MCIN/AEI/10.13039/501100011033/FEDER, UE
20 0264 Karolinska Institutet, the Swedish Cancer Society
2022-01398 Swedish Research Council
67985823 Czech Academy of Sciences
23-04670S Grant Agency of Czech Republic
IJC 2019-042182-I Juan de la Cierva Incorporación Programme
The Pew Charitable Trusts
CA18133 COST (European Cooperation in Science and Technology)
R01 DA0455698 NIH HHS - United States

Class A G protein-coupled receptors (GPCRs) continue to garner interest for their essential roles in cell signalling and their importance as drug targets. Although numerous drugs in the clinic target these receptors, over 60% GPCRs remain unexploited. Moreover, the adverse effects triggered by the available unbiased GPCR modulators, limit their use and therapeutic value. In this context, the elucidation of biased signalling has opened up new pharmacological avenues holding promise for safer therapeutics. Functionally selective ligands favour receptor conformations facilitating the recruitment of specific effectors and the modulation of the associated pathways. This review surveys the current drug discovery landscape of GPCR-biased modulators with a focus on recent advances. Understanding the biological effects of this preferential coupling is at different stages depending on the Class A GPCR family. Therefore, with a focus on individual GPCR families, we present a compilation of the functionally selective modulators reported over the past few years. In doing so, we dissect their therapeutic relevance, molecular determinants and potential clinical applications. LINKED ARTICLES: This article is part of a themed issue Complexity of GPCR Modulation and Signaling (ERNST). To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v182.14/issuetoc.

Celtarys Research S L Santiago de Compostela Spain

Center for Research in Biological Chemistry and Molecular Materials University of Santiago de Compostela Santiago de Compostela Spain

CiberNed Network Center for Neurodegenerative Diseases National Spanish Health Institute Carlos 3 Madrid Spain

Department of Biochemistry and Physiology Faculty of Pharmacy and Food Science Universitat de Barcelona Barcelona Spain

Department of Pharmacology and Cancer Biology Duke University School of Medicine Durham North Carolina USA

Department of Physiology and Pharmacology Karolinska Institutet Stockholm Sweden

Heinrich Heine University Düsseldorf Institut fuer Pharmazeutische und Medizinische Chemie Duesseldorf Germany

Institute for Pharmaceutical and Medicinal Chemistry University of Münster Münster Germany

Institute of Biomedicine Universitat de Barcelona Barcelona Spain

Institute of Physiology Czech Academy of Sciences Prague Czech Republic

Instituto de Química Médica Consejo Superior de Investigaciones Científicas Madrid Spain

Laboratory of Medicinal Chemistry Faculty of Pharmacy and Food Sciences Universitat de Barcelona Barcelona Spain

Laboratory of Molecular Pharmacology Department of Biomedical Sciences Faculty of Health and Medical Sciences University of Copenhagen Copenhagen Denmark

Medicinal Chemistry Research Group and National Drug Discovery and Development Laboratory Research Centre for Natural Sciences Budapest Hungary

Molecular Neurobiology Laboratory Department of Biochemistry and Molecular Biology Universitat de Barcelona Barcelona Spain

School of Chemistry Universitat de Barcelona Barcelona Spain

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25015235
003      
CZ-PrNML
005      
20250731090844.0
007      
ta
008      
250708s2025 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/bph.17301 $2 doi
035    __
$a (PubMed)39261899
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Morales, Paula $u Instituto de Química Médica, Consejo Superior de Investigaciones Científicas, Madrid, Spain
245    10
$a Progress on the development of Class A GPCR-biased ligands / $c P. Morales, MM. Scharf, M. Bermudez, A. Egyed, R. Franco, OK. Hansen, N. Jagerovic, J. Jakubík, GM. Keserű, DJ. Kiss, P. Kozielewicz, O. Larsen, M. Majellaro, A. Mallo-Abreu, G. Navarro, R. Prieto-Díaz, MM. Rosenkilde, E. Sotelo, H. Stark, T. Werner, LM. Wingler
520    9_
$a Class A G protein-coupled receptors (GPCRs) continue to garner interest for their essential roles in cell signalling and their importance as drug targets. Although numerous drugs in the clinic target these receptors, over 60% GPCRs remain unexploited. Moreover, the adverse effects triggered by the available unbiased GPCR modulators, limit their use and therapeutic value. In this context, the elucidation of biased signalling has opened up new pharmacological avenues holding promise for safer therapeutics. Functionally selective ligands favour receptor conformations facilitating the recruitment of specific effectors and the modulation of the associated pathways. This review surveys the current drug discovery landscape of GPCR-biased modulators with a focus on recent advances. Understanding the biological effects of this preferential coupling is at different stages depending on the Class A GPCR family. Therefore, with a focus on individual GPCR families, we present a compilation of the functionally selective modulators reported over the past few years. In doing so, we dissect their therapeutic relevance, molecular determinants and potential clinical applications. LINKED ARTICLES: This article is part of a themed issue Complexity of GPCR Modulation and Signaling (ERNST). To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v182.14/issuetoc.
650    12
$a receptory spřažené s G-proteiny $x metabolismus $x agonisté $7 D043562
650    _2
$a lidé $7 D006801
650    _2
$a ligandy $7 D008024
650    _2
$a zvířata $7 D000818
650    12
$a objevování léků $7 D055808
650    _2
$a signální transdukce $x účinky léků $7 D015398
650    _2
$a vyvíjení léků $7 D000076722
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Scharf, Magdalena M $u Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden $1 https://orcid.org/0000000233053956
700    1_
$a Bermudez, Marcel $u Institute for Pharmaceutical and Medicinal Chemistry, University of Münster, Münster, Germany $1 https://orcid.org/0000000274213282
700    1_
$a Egyed, Attila $u Medicinal Chemistry Research Group and National Drug Discovery and Development Laboratory, Research Centre for Natural Sciences, Budapest, Hungary
700    1_
$a Franco, Rafael $u Molecular Neurobiology Laboratory, Department of Biochemistry and Molecular Biology, Universitat de Barcelona, Barcelona, Spain $u CiberNed. Network Center for Neurodegenerative Diseases, National Spanish Health Institute Carlos III, Madrid, Spain $u School of Chemistry, Universitat de Barcelona, Barcelona, Spain $1 https://orcid.org/0000000325494919
700    1_
$a Hansen, Olivia K $u Laboratory of Molecular Pharmacology, Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
700    1_
$a Jagerovic, Nadine $u Instituto de Química Médica, Consejo Superior de Investigaciones Científicas, Madrid, Spain
700    1_
$a Jakubík, Jan $u Institute of Physiology Czech Academy of Sciences, Prague, Czech Republic $1 https://orcid.org/0000000217371487 $7 xx0281420
700    1_
$a Keserű, György M $u Medicinal Chemistry Research Group and National Drug Discovery and Development Laboratory, Research Centre for Natural Sciences, Budapest, Hungary
700    1_
$a Kiss, Dóra Judit $u Medicinal Chemistry Research Group and National Drug Discovery and Development Laboratory, Research Centre for Natural Sciences, Budapest, Hungary
700    1_
$a Kozielewicz, Pawel $u Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden $1 https://orcid.org/0000000314143566
700    1_
$a Larsen, Olav $u Laboratory of Molecular Pharmacology, Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
700    1_
$a Majellaro, Maria $u Celtarys Research S.L., Santiago de Compostela, Spain
700    1_
$a Mallo-Abreu, Ana $u Center for Research in Biological Chemistry and Molecular Materials (CIQUS), University of Santiago de Compostela, Santiago de Compostela, Spain $u Laboratory of Medicinal Chemistry (CSIC Associated Unit), Faculty of Pharmacy and Food Sciences, Universitat de Barcelona, Barcelona, Spain $u Institute of Biomedicine (IBUB), Universitat de Barcelona, Barcelona, Spain
700    1_
$a Navarro, Gemma $u CiberNed. Network Center for Neurodegenerative Diseases, National Spanish Health Institute Carlos III, Madrid, Spain $u Department of Biochemistry and Physiology, Faculty of Pharmacy and Food Science, Universitat de Barcelona, Barcelona, Spain $1 https://orcid.org/0000000346540873
700    1_
$a Prieto-Díaz, Rubén $u Center for Research in Biological Chemistry and Molecular Materials (CIQUS), University of Santiago de Compostela, Santiago de Compostela, Spain
700    1_
$a Rosenkilde, Mette M $u Laboratory of Molecular Pharmacology, Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark $1 https://orcid.org/0000000196003254
700    1_
$a Sotelo, Eddy $u Center for Research in Biological Chemistry and Molecular Materials (CIQUS), University of Santiago de Compostela, Santiago de Compostela, Spain
700    1_
$a Stark, Holger $u Heinrich Heine University Düsseldorf, Institut fuer Pharmazeutische und Medizinische Chemie, Duesseldorf, Germany $1 https://orcid.org/0000000333361710 $7 jn19990008168
700    1_
$a Werner, Tobias $u Heinrich Heine University Düsseldorf, Institut fuer Pharmazeutische und Medizinische Chemie, Duesseldorf, Germany
700    1_
$a Wingler, Laura M $u Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, North Carolina, USA
773    0_
$w MED00009383 $t British journal of pharmacology $x 1476-5381 $g Roč. 182, č. 14 (2025), s. 3249-3300
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39261899 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250708 $b ABA008
991    __
$a 20250731090839 $b ABA008
999    __
$a ok $b bmc $g 2366223 $s 1252360
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 182 $c 14 $d 3249-3300 $e 20240911 $i 1476-5381 $m British journal of pharmacology $n Br J Pharmacol $x MED00009383
GRA    __
$a RRF-2.3.1-21-2022-00015 $p National Office of Research, Development and Innovation
GRA    __
$a FJC2021-047571-I $p Ministerio de Ciencia e Innovación
GRA    __
$a PID2020-118511RB-I00 $p Ministerio de Ciencia e Innovación
GRA    __
$a PID2021-124010OB-100 $p Ministerio de Ciencia e Innovación
GRA    __
$a PID2021-126600OB-I00 $p Ministerio de Ciencia e Innovación
GRA    __
$a PID2021-127833OB-I00 $p Ministerio de Ciencia e Innovación
GRA    __
$a PID2022-139197OA-I00 $p Ministerio de Ciencia e Innovación
GRA    __
$a 20 0264 $p Cancerfonden
GRA    __
$a R01 DA0455698 $p NIH HHS $2 United States
GRA    __
$a 470002134 $p German Research Foundation
GRA    __
$a GRK 2158 $p German Research Foundation
GRA    __
$a PG-22-0379-H-01 $p Swedish Society for Medical Research
GRA    __
$a NAP 3.0 $p Hungarian Academy of Sciences
GRA    __
$a ED431B 2020/43 $p Consellería de Cultura, Educación e Ordenación Universitaria of the Galician Government
GRA    __
$a ED431G 2019/03 $p Centro Singular de Investigación de Galicia Accreditation 2019-2022
GRA    __
$a FJC2021-047571-I $p MCIN/AEI/10.13039/501100011033/FEDER, UE
GRA    __
$a 20 0264 $p Karolinska Institutet, the Swedish Cancer Society
GRA    __
$a 2022-01398 $p Swedish Research Council
GRA    __
$a 67985823 $p Czech Academy of Sciences
GRA    __
$a 23-04670S $p Grant Agency of Czech Republic
GRA    __
$a IJC 2019-042182-I $p Juan de la Cierva Incorporación Programme
GRA    __
$p The Pew Charitable Trusts
GRA    __
$a CA18133 $p COST (European Cooperation in Science and Technology)
GRA    __
$a R01 DA0455698 $p NIH HHS $2 United States
LZP    __
$a Pubmed-20250708

Najít záznam

Citační ukazatele

Možnosti archivace